Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Diabetes Mellitus, Type 2 Subjects with T2DM as defined by the of the ADA and/or recognized by WHO Expert Committee on the Diagnosis and Classification of Diabetes Mellitus [American Diabetes Association, 2004], for at least 3 months preceding screening (see Section 15.3, Appendix 3:, "Diagnosis and Classification of Diabetes Mellitus") To be eligible for Randomization into the trial, a subject must satisfy all of the following glycemic HbA1c level via central laboratory at the pre-screening visit If HbA1c ≥ 8.0% but ≤ 10.0%: subject may proceed to Randomization If HbA1c ≥ 7.8% but < 8.0%, subject not eligible to proceed, but may be retested once to establish (or lack thereof). If HbA1c level ≥ 8.0% upon retest, subject is eligible to proceed; otherwise they should be withdrawn If HbA1c < 7.8%, subject not eligible to proceed (no retest allowed) FPG level via central laboratory at the pre-screening visit must be < 270 mg/dL (15.0 mmol/L). FPG may be retested within a week to confirm (or lack thereof) Concurrent T2DM therapy Diet and/or exercise treated: Must not have taken antidiabetic medication for at least 2 months prior to the pre-screening visit, OR Metformin monotherapy: Subjects entering the study on metformin must be on the same dose, formulation and regimen of metformin for at least 2 months prior to the pre-screening visit, AND  Metabolic Disease including Diagnosis of Type 1 diabetes mellitus Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 1 month prior to Screening, and who have a screening thyroid stimulating hormone (TSH) within the upper limit of normal may participate) Significant weight gain or loss (defined as > 5% of total body weight) within the 3 months prior to Screening Previous use of insulin for treatment of hyperglycemia within 3 months of Screening History of recent clinically significant cardiovascular disease including History or ECG evidence of prior myocardial infarction within 6 months prior to Screening Current unstable angina or history of unstable angina in past 6 months Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery that is either planned or occurred in the 6 months prior to Screening Clinically significant arrhythmia or valvular heart disease